等待开盘 11-17 09:30:00 美东时间
-0.270
-2.62%
Keros Therapeutics announced the approval of a $5 million share repurchase program following a $20 million milestone payment from Takeda Pharmaceuticals and the initiation of its ELRiSE MF clinical trial. The program allows the company to repurchase shares in the open market, with timing and amounts dependent on market conditions. Keros, focused on TGF-β-related disorders, is developing therapies like rinvatercept and elritercept for muscular dys...
11-16 21:01
11月12日,Keros Therapeutics(KROS)收涨2.25%,报9.54美元,成交额210.85万美元,市值1.87亿美元。 行情数据 • 开盘...
11-12 07:43
11月10日,Keros Therapeutics(KROS)收跌2.03%,报9.17美元,成交额135.18万美元,市值1.8亿美元。 行情数据 • 开盘价...
11-10 07:44
Keros Therapeutics 最新财报显示,公司2026财年第3季度实现营业收入4000.9万美元,同比增长180.53%;净利润为1415.3万美元...
11-07 13:00
Keros Therapeutics ( ($KROS) ) has provided an announcement. On November 5, 202...
11-06 05:47
11月3日,Keros Therapeutics(KROS)收跌2.54%,报10.76美元,成交额149.36万美元,市值2.13亿美元。 行情数据 • 开盘...
11-03 07:36
10月27日,Keros Therapeutics(KROS)收涨0.44%,报11.33美元,成交额127.66万美元,市值2.25亿美元。 行情数据 • 开...
10-27 06:37
10月20-22日上海黄浦江畔,2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势,更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:42
Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") fami...
09-28 20:03
Keros Therapeutics announced the initiation of a Phase 2 clinical trial for rinvatercept in patients with Duchenne muscular dystrophy (DMD), with the first patient dosed. Rinvatercept aims to modulate muscle and bone biology by targeting myostatin and activin A. The trial will assess safety, tolerability, and potential functional improvements in both ambulatory and non-ambulatory DMD patients. Keros is developing rinvatercept for DMD and amyotrop...
09-28 12:00